IMR Press / FBL / Volume 8 / Issue 6 / DOI: 10.2741/996

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Immunotherapy of allergic bronchopulmonary aspergillosis: a clinical and experimental approach
Show Less
1 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya St., 16/10, Moscow, Russia
2 Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226 and the V. A. Medical Center, 5000 West National Avenue, Milwaukee, WI 53295 USA

Academic Editor: Viswanath Kurup

Front. Biosci. (Landmark Ed) 2003, 8(6), 92–101;
Published: 1 January 2003
(This article belongs to the Special Issue Allergic aspergillosis)

Allergic bronchopulmonary aspergillosis (ABPA) is a severe allergic pulmonary complication caused by the saprophytic fungus Aspergillus fumigatus. The present review examines the pathogenesis of this disease describing in detail the role of innate and acquired immunity in the induction of sensitivity to A.fumigatus. Different approaches in developing specific immunotherapeutic treatments such as induction of anergy, regulatory cells, a switch from Th2 to Th1 type of immune response, CpG and genetic immunization and the usage of altered peptides or modified allergens are critically examined.

Specific immunotherapy
Regulatory T-cells
Naked DNA
Back to top